UNSPSC 51313113: Chlorcyclizine dihydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61Y56T95YL, chemically known as piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-, hydrochloride (1:2), but more generally known as chlorcyclizine dihydrochloride, which bears US NIH Compound Identifier 101605. European Medicines Agency schedules chlorcyclizine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06178MIG.

Most nations, for tariff purposes, schedule chlorcyclizine dihydrochloride under HS 29335995. SMILES: CN1CCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.CL.

UNSPSC 51313113 Chlorcyclizine dihydrochloride is a Commodity code that captures pharmaceutical products procured by state and local health agencies, primarily through cooperative purchasing arrangements and competitive bidding processes. The recent opportunities tagged to this code show state and local governments buying generic pharmaceuticals, naloxone kits, and over-the-counter health products for distribution through authorized wholesalers and direct delivery to community health facilities. Issuing bodies include state health and human services agencies, county health departments, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work involves vendor qualification around Good Manufacturing Practices, Drug Supply Chain Security Act compliance, pricing transparency, and logistics management including insurance coverage and drug-free workplace certification.

Recent activity clusters in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, requiring electronic bid submission through the county's e-Procurement Portal with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracts between state agencies and pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson), with evaluation weighted 75 percent on price competitiveness and awards effective July 1, 2026.